Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 24, Issue 39, Pages 4646-4651Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612825666190110143258
Keywords
PI3K/AKT/mTOR pathway; microRNAs; esophageal cancer; rapamycin; translation; transcription
Categories
Funding
- Mashhad University of Medical Sciences
Ask authors/readers for more resources
The Phosphatidylinositol 3-kinase/AKT/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) pathway has a critical regulatory role in cell biology including translation, transcription, and autophagy. Dysregulation of this pathway is involved in the pathogenesis, development, and prognosis of esophageal cancer that has been assessed in the recent years and its potential as a target in therapy. This report summarizes the current knowledge about PI3K/AKT/mTOR pathway and its cross-talk with a focus on the value of targeting this pathway as a potential therapeutic target in the treatment of esophageal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available